This page has been archived on the Web

Information identified as archived is provided for reference, research or recordkeeping purposes. It is not subject to the Government of Canada Web Standards and has not been altered or updated since it was archived. Please contact us to request a format other than those available.

Health product recall

Monolisa Hcv Ag-Ab Ultra V2

Brand(s)
Last updated

Summary

Product
Monolisa Hcv Ag-Ab Ultra V2
Issue
Medical devices - Performance
What to do

Contact the manufacturer if you require additional information. 

Audience
Healthcare

Affected products

Affected products Lot or serial number Model or catalogue number
Monolisa Hcv Ag-Ab Ultra V2 3B1066 3A0065 72561

Issue

During an internal assessment, sensitivity to the HCV antigen was reduced for samples near the detection limit. Due to the reduced sensitivity of the HCV antigen test, recent infections by HCV cannot be detected in patient samples as early as with previous lots of Monolisa HCV Ag-Ab ULTRA V2. For these lots, there is no impact on the detection of seroconversions of antibodies against HCV.

Recall start date: December 1, 2023

Additional information

Details
Original published date:
Alert / recall type
Health product recall
Category
Health products - Medical devices - Microbiology
Companies
Bio-Rad
3 Boulevard Raymond Poincare, Marnes-La-Coquette, Marne, France, 92430
Published by
Health Canada
Audience
Healthcare
Recall class
Type II
Identification number
RA-74735

Get notified

Receive emails about new and updated recall and safety alerts.

Subscribe